Evidence map›Paper›PMID 33563218›Full record

Observational studyBMC infectious diseases2021

Clinical characteristics and outcomes of critically ill COVID-19 patients in Tokyo: a single-center observational study from the first wave.

Aya Banno, Toru Hifumi, Hiroshi Okamoto, Minori Masaki, Koichiro Seki, Shutaro Isokawa, Norio Otani, Kuniyoshi Hayashi, Shinichi Ishimatsu

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Intensive care burden of COVID-19 in tertiary care hospitals during the first year of outbreak in Kawasaki City, Japan: A retrospective cohort study.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2022
    Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Aya BannoDepartment of Anesthesia and Intensive Care, St. Luke's International Hospital, 9-1 Akashicho, Chuo-ku, Tokyo, 104-8560, Japan. ayabanno@luke.ac.jp.ORCID http://orcid.org/0000-0001-8279-0429
Toru HifumiDepartment of Emergency and Critical Care Medicine, St. Luke's International Hospital, Tokyo, Japan.
Hiroshi OkamotoDepartment of Anesthesia and Intensive Care, St. Luke's International Hospital, 9-1 Akashicho, Chuo-ku, Tokyo, 104-8560, Japan.
Minori MasakiDepartment of Anesthesia and Intensive Care, St. Luke's International Hospital, 9-1 Akashicho, Chuo-ku, Tokyo, 104-8560, Japan.
Koichiro SekiDepartment of Anesthesia and Intensive Care, St. Luke's International Hospital, 9-1 Akashicho, Chuo-ku, Tokyo, 104-8560, Japan.
Shutaro IsokawaDepartment of Emergency and Critical Care Medicine, St. Luke's International Hospital, Tokyo, Japan.
Norio OtaniDepartment of Emergency and Critical Care Medicine, St. Luke's International Hospital, Tokyo, Japan.
Kuniyoshi HayashiGraduate School of Public Health, St. Luke's International University, Tokyo, Japan.
Shinichi IshimatsuDepartment of Emergency and Critical Care Medicine, St. Luke's International Hospital, Tokyo, Japan.
St. Luke's International Hospital · JPSt. Luke's International University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany studies have been published about critically ill coronavirus disease 2019 (COVID-19) during the early phases of the pandemic but the characteristic or survival of critically ill Japanese patients have not yet been investigated. We sought to investigate the characteristics, inflammatory laboratory finding trends, and outcomes among critically ill Japanese patients who were admitted to the intensive care unit (ICU) with the first wave of COVID-19.

methodsA retrospective observational study was performed in a single institution in the center of Tokyo. Laboratory-confirmed COVID-19 patients admitted to the ICU from March 19 to April 30, 2020 were included. Trends for significant inflammatory laboratory findings were analyzed. In-hospital death, days of mechanical ventilation or oxygen supplementation, days of ICU or hospital stay were followed until May 26, 2020.

resultsTwenty-four patients were included. Median age was 57.5 years, and 79% were male. The neutrophil-to-lymphocyte ratio was elevated to a median of 10.1 on admission and peaked on Day 10 of illness. Seventeen patients were intubated on Day 11 of illness and received mechanical ventilation. One patient underwent extracorporeal membrane oxygenation. The majority (88%) received systemic steroids, including 16 patients who received high dose methylprednisolone (500-1000 mg). Favipiravir was used in 38% of patients. Two patients, including 1 who refused intensive care, died. Eighteen patients were discharged. Median length of ICU and hospital stay for all patients was 6 and 22 days, respectively. Median length of ventilator dependency was 7 days. Four patients underwent a tracheostomy and received prolonged ventilation for more than 21 days. One patient receiving mechanical ventilation died. All survivors discontinued ventilator use.

conclusionsMortality was remarkably low in our single institutional study. Three survivors received mechanical ventilation for more than 3 weeks. Trends of clinically significant laboratory markers reflected the clinical course of COVID-19.

Indexed as

AdultAgedAged, 80 and overAntiviral AgentsCOVID-19C-Reactive ProteinCritical IllnessExtracorporeal Membrane OxygenationFemaleFibrin Fibrinogen Degradation ProductsHospitalizationHumansIntensive Care UnitsLength of StayLeukocyte CountMaleAntiviral AgentsC-Reactive ProteinFibrin Fibrinogen Degradation Productsfibrin fragment DMethylprednisoloneCoronavirus diseaseCOVID-19FavipiravirICUJapanMortalitySystemic steroid

Identifiers

PMID33563218
PMCPMC7871305
OpenAlexW3127065953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.